SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Bennett who wrote (621)10/20/2000 1:47:44 PM
From: Biomaven   of 666
 
Switching now gives up the $5 premium between CLTR and CRXA, so there's no free lunch. That premium should reduce (but not to 0) if the BLA is accepted.

So it's up to you whether you prefer the $5 or prefer to sleep better at nights. (Of course the GLIA non-merger is a lessen for those that think they don't care about sleeping well).

One reasonable compromise is to switch part of your holding - if the merger bites the dust CRXA should regain some of the losses it made when the merger was first announced.

Peter

P.S. I agree that this was a very strange deal from the point of view of CLTR. Why not just wait until at least the BLA was accepted?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News